Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Adalimumab Monotherapy in RA (ADACTA)
NCT01119859Phase 4Completed
- Sponsor
- Roche
- Start
- May 2010
- Primary completion
- Jan 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Change From Baseline in Disease Activity Score 28 at 24 weeks. Started May 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01119859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01119859.